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Abstract: Human sex determining region Y-box 2 (SOX2) is an important transcriptional factor involved in the pluripo-
tency and stemness of human embryonic stem cells. SOX2 plays important roles in maintaining cancer stem cell ac-
tivities of melanoma and cancers of the brain, prostate, breast, and lung. SOX2 is also a lineage survival oncogene 
for squamous cell carcinoma of the lung and esophagus. Spontaneous cellular and humoral immune responses 
against SOX2 present in cancer patients classify it as a tumor-associated antigen (TAA) shared by lung cancer, glio-
blastoma, and prostate cancer among others. In this study, B-cell epitopes were predicted using computer-assisted 
algorithms. Synthetic peptides based on the prediction were screened for recognition by serum samples from can-
cer patients using ELISA. Two dominant B-cell epitopes, SOX2:52-87 and SOX2:98-124 were identified. Prostate 
cancer, glioblastoma and lung cancer serum samples that recognized the above SOX2 epitopes also recognized 
the full-length protein based on Western blot. These B-cell epitopes may be used in assessing humoral immune 
responses against SOX2 in cancer immunotherapy and stem cell-related transplantation. 
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Introduction
SOX2 is a single-exon gene located on chromo-
some 3q26.3-q27 and encodes a 317 amino 
acid protein with a characteristic high mobility 
group (HMG) DNA-binding domain [1]. SOX2 
belongs to the SOX family of transcriptional fac-
tors that include at least 14 members such as 
SOX1, SOX4, SOX9, SOX11 and so on [2]. SOX2 
is highly expressed in the nervous system [3] 
during embryonic development but is down-
regulated when neural cells exit the cell cycle 
and differentiate [4]. SOX2 is also found in 
adult granule cells of the cerebellum [3], brain, 
testis, and to a less extent the alimentary canal 
and prostate [5]. SOX2 is probably best known 
for its role together with OCT4, KLF4 and c-MYC 
[6, 7], or OCT4, NANOG, and LIN28 [8] in repro-
gramming human and mouse fibroblasts into 
induced pluripotent stem cells or iPS cells. 
SOX2 expressions are found in cancerous cells 
that have acquired stem cell properties or the 
so-called cancer stem cells. For example, pedi-
atric brain tumors including medulloblastomas 
and glioblastomas contained stem cell like pop-
ulations with high levels of SOX2 expression. 
This population of cells formed neurospheres 
that can be passaged at clonal density and are 
able to self-renew [9]. SOX2 was also upregu-
lated in adult medulloblastoma and glioblasto-
ma [10, 11] and believed to play roles to main-
tain tumor stemness properties and tumo- 
rigenicity. Similarly, SOX2 overexpression was 
found in cancer stem cells from prostate cancer 
[12], lung cancer [13], breast cancer [14], 
esophageal cancer [15], and melanoma [16] 
that shared the same neuroectodermal lineage 
in development. For example, not only was 
SOX2 overexpressed in a prostate cancer popu-
lation with stem cell properties, but ectopic 
overexpression of SOX2 contributed to the 
acquired stemness properties including andro-
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gen independence in vitro [17, 18]. In squa-
mous cell carcinomas of the lung, SOX2 expres-
sion was required for proliferation and ancho- 
rage-independent growth of lung cell lines; 
while ectopic expression of SOX2 was able to 
transform immortalized tracheobronchial epi-
thelial cells, showing expression of markers of 
both squamous differentiation and pluripoten-
cy [15]. In human lung adenocarcinomas, SOX2 
was specifically expressed in a side population 
with stem cell properties in vitro; while SOX2 
knockdown of LHK2 side population cells by 
gene-specific siRNA completely abrogated 
tumorigenicity in vivo [13].
SOX2 is also known for inducing spontaneous 
antibody and T cell responses in various cancer 
patients, and therefore qualified as a TAA. A 
striking feature of the spontaneous immunity 
against SOX2 is that autoantibodies (autoAb) 
are even detected with serum dilutions of up to 
1:106 in some cancer patients [5, 19]. High-
titer and class-switched autoAb were observed 
in 15% of small cell lung cancer (SCLC), 23% of 
non-small cell lung cancer (NSCLC), 22% of 
breast cancer, and 19% of ovarian cancer (Ali 
Gure, unpublished data). T cell responses 
against SOX2 were also demonstrated in more 
than 70% monoclonal gammopathy of unknown 
significance and SCLC patients [20], which 
were associated with a better prognosis [19].
With the potential implications of autoAb again- 
st SOX2 as biomarkers in cancer detection, 
responses to therapy, and prognosis as well as 
monitoring teratoma formation in transplanta-
tion of pluripotent stem cells, B cell epitopes 
from human SOX2 were identified and validat-
ed in this study.
Materials and methods
Prediction of B-cell epitopes using computer-
assisted algorithm 
The hydrophilicity/hydrophobicity analysis of 
SOX2 was calculated based on the Kyte-
Doolittle method using a window size of 9. The 
program of RVP-NET: real value prediction of 
solvent accessibility at web site http://gibk26.
bse.kyutech.ac.jp/jouhou/shandar/netasa/
rvp-net/ was used for predicting secondary 
structures of the SOX2 protein. A window of 12 
amino acid residues was used to obtain the sol-
vent accessibility plot using the prediction 
program.
Preparation of recombinant proteins and syn-
thetic peptides
Recombinant SOX2 protein was purified from 
bacteria as previously reported [5]. Synthetic 
peptides used in this study were made using a 
solid-phase method on a peptide synthesizer at 
Genscript Inc (Piscataway, NJ). The molecular 
weight of individual peptide was evaluated by 
mass spectrometry to confirm the identity 
before product release from the manufacturer. 
Peptides were re-suspended in DMSO solution 
at 20 mg/ml and stored at –20°C until use.
Detection of SOX2 autoAb in patients’ serum 
samples and confirmation with Western blot 
Sera from patients with glioblastoma, prostate 
cancer, and lung cancer were collected at the 
UCLA medical center under approved IRB pro-
tocols. All serum samples were from histologi-
cally confirmed cancer patients; however, clini-
cal stages of each sample varied from patient 
to patient. Serum samples were stored at 
–20°C until being analyzed. 
Antigen-coated plates were prepared using 
250 ng/well purified SOX2 protein or 60 ng/
well SOX2 synthetic peptides of 20-36 amino 
acid residues in 100 µL carbonate bicarbonate 
buffer. These antigens were adsorbed over-
night to coat a 96-well MaxiSorp plate (Nunc, 
Denmark) at 4°C. Control plates were coated 
with 60 ng/well of a ß-galactosidase peptide. 
Plates were blocked with 5% Fetal Bovine 
Serum (FBS) in PBST (PBS plus 0.05% Tween-
20) for at least 2 hours, washed with PBST, and 
loaded with 100 µL of diluted serum samples. 
All serum samples were diluted at 1:10, 1:20, 
and 1:50 with PBST containing 5% FBS unless 
otherwise specified. Each sample at the three 
different dilutions was loaded onto pre-coated 
ELISA plates. After a 2-hour incubation at room 
temperature, plates were washed, and loaded 
with secondary antibodies (goat anti-human 
immunoglobulin conjugated with horseradish 
peroxidase, Sigma Co., St. Louis, MO) diluted 
with 5% FBS in PBST. Plates were developed 
after a one-hour incubation, and absorbance at 
450 nm was read by using an ELISA reader. The 
cut-off value was defined as the mean optimal 
density (OD) value plus 3 times standard deri-
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Figure 1. A. A hydropathical profile predicted using the Kyte-Doolittle method with a window size of 9 amino acid residues; B. Computer-assisted prediction of B cell 
epitopes from human SOX2; C. Peptides synthesized for screening B cell epitopes from SOX2; D. Human SOX family members that share homology with the identified 
B cell epitopes are highlighted. Initial alignment of SOX proteins and B-cell epitopes was performed using ClustalW2 alignment tool from EMBL-EBI website (www.
ebi.ac.uk/tools/msa/clustalw2). Accession numbers for SOX proteins are provided in parentheses.
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vations of healthy donors (HD). If an OD value 
against a peptide exceeded the cut-off from at 
least 2 of the 3 dilutions, the sample was 
regarded as positive. 
Western blotting analysis was performed by 
SDS-PAGE followed by electro-transfer of pro-
teins onto low fluorescence Immobilon-FL PVDF 
membrane (Millipore, MA). Immunoblots were 
probed using diluted patients’ serum samples 
reactive to the peptides based on ELISA screen-
ing. The secondary Ab used was goat anti-
human IgG conjugated with horse redish per-
oxidase as previously described [21]. Immu- 
noblot was developed using Pierce ECL Plus 
reagent (Thermo Scientific, IL) and visualized 
using Typhoon 9410 Imager (GE Healthcare, 
Pittsburgh, PA) at UCLA Biological Chemistry 
Imaging Facility. Images were analyzed with 
ImageQuant software.
Results 
Prediction of B-cell epitopes from cancer/stem 
cell antigen SOX2 
The 317-amino acid protein, SOX2 has a hydro-
philic N-terminal domain and a relatively hydro-
phobic C-terminal domain based on hydropathi-
cal profiles predicted using the Kyte-Doolittle 
method [22] (Figure 1A). Using a window size of 
9, negative peaks suggest the likelihood of 
hydrophobic regions of globular proteins. It is 
known that linear epitopes of small sequence 
segments are usually peptides conferring rela-
tively loose conformations, such as the beta-
turn and coil conformations of hydrophobic 
regions [23], and most linear epitopes consist-
ed of at least 7 amino acid residues, we thus 
used a window of 12 amino acid residues to 
obtain the solvent accessibility plot (Figure 1B). 
Essentially, the N-terminal hydrophilic domain 
was predicted to be exposed on the surface of 
the protein, which was accessible to the sol-
vent while the C-terminal domain was likely bur-
ied in the interior of the protein. Therefore, the N-ter- 
minal might have direct contact with immuno-
globulin molecules on the surface of a plasma 
B cell and contain B-cell epitopes recognized by 
Ab present in patients’ sera. Three peptides of 
20-40 amino acid residues with highest pre-
dicted ASA scores were synthesized (Figure 
1C). Homology alignments based on the pep-
tide sequences show both peptide fragments 
had significant (> 80%) homologies with some 
other members of the SOX gene family, such as 
SOX3, SOX14, and SOX21 (Figure 1D). 
Identification of SOX2-derived B cell epitopes 
recognized by Ab present in patients’ serum 
samples
To identify the B-cell epitopes among the pep-
tides, which were recognized by serum-derived 
Ab, serum samples from 19 patients with glio-
blastoma, 19 patients with prostate cancer, 
and 5 patients with lung cancer were used to 
screen for recognition of the three synthetic 
Figure 2. Screening of patients’ serum samples for recognition of SOX-2 B cell epitopes using ELISA. Serum samples 
from 8 HD and 19 glioblastoma patients (A) and 19 prostate cancer and 5 lung cancer patients (B) were used to 
screen for recognition of SOX2 peptides predicted as B cell epitopes.
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peptides. Eight healthy donors were used to 
establish the cuttoff value for a seropositve 
reaction, which is the average OD (OD agasint 
control peptide subtracted from OD against the 
peptide of interest) from the healthy donors 
plus three times of the standard derivation as 
previously reported in similar experiments. 
Recognition of two peptides, SOX2:52-87 and 
SOX2:98-124, was observed in 1 glioblastoma 
patient (#2783, Figure 2A) and 2 prostate can-
cer patients (#1038 and 1131, Figure 2B). 
None of the samples recognized SOX2:5-37 in 
the screening effort (data not shown).
Verification of SOX2 peptide epitopes by West-
ern blot 
To determine that sera reacting with the 2 syn-
thetic peptides also recognized the full-length 
SOX2 protein, ELISA and Western blot were 
conducted using the above-referenced 3 sero-
positive samples as well as a previously known 
sero-positive sample (#KHA-71, small cell lung 
cancer patient). Both ELISA and Western blot 
experiments indicated that the 3 seropositive 
patients identified by screening against the 
peptides recognized the full-length SOX2 
recombinant protein. The previously known 
seropositive patient (#KHA-71) served as a pos-
itive control; meanwhile a prostate cancer 
serum sample that did not react to these tar-
gets served as a negative control (Figure 3). 
None of the seropositive samples had signifi-
cant recognition of the negative control pro-
teins, which contained more than 6 μg HEK293T 
cell lysates in each lane. These data recon-
firmed that the SOX2:52-87 and SOX2:98-124 
peptides served as B-cell epitopes recognized 
by serum samples from various cancer patients.
Discussion
Recent success in the therapeutic arena using 
immune checkpoint blockers [24, 25] has indi-
cated the importance of tipping the balance of 
spontaneous anti-tumor immunity in vivo. 
Immune responses against TAA have also attra- 
cted significant attention as emerging cancer 
biomarkers [26]. Comparing to classic biomark-
ers, immune responses such as autoAb res- 
ponses against TAA may be better surrogates 
for cancer-related inflammation, immunocom-
petence of the host, and the immunogenicity of 
the endogenously arising cancer. With the 
development of more sensitive and multiplex 
technologies, autoAb against TAA with signifi-
cant roles in oncogenesis (such as SOX2) may 
open new doors for biomarkers in cancer detec-
tion, prognosis and responses to therapy. As a 
TAA shared by a couple of human cancers, 
autoAb responses against SOX2 peptide epit-
opes may find utilities in the above-referenced 
fields. Other members of the SOX family are 
also expressed in cancer tissues, including 
lung, brain, pancreas, stomach, and breast 
cancers [27]. At least one of them, SOX4 has 
been found to induce T cell and B cell respons-
es in small cell lung cancer patients [27].
It is also noteworthy that autoAb responses 
against dominant peptide epitopes may over-
look conformational epitopes preserved among 
Figure 3. Validation of autoAb responses against B cell epitopes derived from SOX2 using a seropositive sample 
(#KHA-71) known to contain high titer autoAb against SOX2 as control, by ELISA (A) and by Western blot on the full-
length SOX2 protein (B). In the Western blot, about 6 μg lysates from HEK293T cells, labeled as H, were used as 
negative controls side by side with 200 ng purified recombinant SOX2 protein, labeled as S.
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full-length protein antigens. However, more 
sensitive technology platforms such as those 
using microspheres (Luminex Corp., Austin, TX) 
may achieve high sensitivity by compensating 
the loss of conformational epitopes based on 
our previous experience [28]. Even though 
autoAb responses against the currently descri- 
bed SOX2 epitopes only have limited sensitivi-
ties, multiplex technologies allow us to mea-
sure autoAb against a panel rather than indi-
vidual targets and develop assays in conjunction 
with conventional cancer biomarkers such as 
prostate specific antigen (PSA) to improve sen-
sitivities and specificities for certain cancer 
types [28]. 
SOX2 represents an excellent example of a pro-
tein that plays important roles in both oncogen-
esis and pluripotency. Interestingly, the same 
unique properties that make human pluripo-
tent stem cells greatly promising, namely self-
renewal and pluripotency, also directly contrib-
ute to their unbridled tumorigenicity when 
organs are transplanted into human hosts. 
Indeed, it is reasonable to predict that human 
pluripotent stem cells are the archetype of 
tumor-forming stem cells, and unless their 
tumorigenicity fully attenuated, it will represent 
a significant threat in the clinical application of 
stem cell-based therapies. In this regards, 
SOX2-derived B cell epitopes may also find 
great promise in monitoring tumorigenicity, 
such as teratoma formation of pluripotent stem 
cell-based therapies in the future.
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